Pharmacology podcasts

Anna Truzzi and Luca Pellegrino discuss experiments on a historical antibacterial preparation and the sources of bias in AI systems. An external segment with Ian Scott and Ilaria Zanardi explores elephant communication, including low-frequency sound, long-distance signalling and the evidence for individually distinctive calls.

Hosted by Anna Truzzi, Luca Pellegrino

Francesca and Ilaria discuss taste-receptor research, mitochondrial biology and a reported ALS case study involving an antisense oligonucleotide treatment. Giuliana Galati interviews University of Padua physicist Francesco Recchia about nuclear phenomenology. The episode links these discussions to the underlying research papers and distinguishes a clinical case report from established treatment evidence.

Hosted by Francesca Cecilia Lauta, Ilaria Zanardi

Rafael Rosengarten and BioPharmaTrend co-founder Andrii Buvailo discuss how to assess progress in AI-assisted drug discovery. They trace the move from individual computational tasks to connected research workflows and question whether counting AI-associated drug candidates captures the technology’s value. Topics include research productivity, trial design, biomarkers, human expertise and the use of patient-derived data, organoids and other representative biological systems to improve translation. The conversation also considers why AI has become polarising and how specialised models may fit into pharmaceutical research.

Jonathan Long discusses the expanding scientific study of peptides, from improved methods for discovering molecules in the body to the success of GLP-1 medicines. The conversation distinguishes research progress from untested wellness claims and examines the search for compounds that reproduce aspects of exercise biology.

Hosted by Nicholas Weiler

Tim Wahlberg of CAS speaks with Rafael Rosengarten about the role of curated chemical knowledge in AI-assisted drug discovery. They examine scientific data quality, harmonisation and expert curation, and consider how reliable information can help researchers formulate questions and evaluate answers from large language models.

Hosted by Rafael Rosengarten

Scientific American's Science Quickly examines an early pilot trial of psilocybin-assisted therapy for people with long-term anorexia. The episode carefully discusses reported changes in symptoms and motivation, possible neuroplasticity mechanisms, the small uncontrolled sample and the need for larger randomized studies and clinical safeguards.

Daphne Koller of insitro discusses the differences between finding predictive patterns and identifying interventions that improve disease outcomes. The conversation examines biological data scarcity, structure and causality, failures in drug development and the limits of speeding up wet-lab work with AI agents. It also considers foundation models for biology, generalization beyond observed data, human evidence and scientific discovery. Hosted by Ravid Shwartz Ziv and Allen Roush. Watch the full conversation on the publisher’s YouTube channel.

Hosted by Ravid Shwartz Ziv, Allen Roush

Jacob Hooker of Sensorium Therapeutics speaks with Rafael Rosengarten about investigating plant-derived compounds for psychiatric and neurological drug development. They discuss ethnobotanical records, knowledge graphs and AI as tools for generating hypotheses, alongside the medicinal chemistry and clinical testing needed to turn potential leads into medicines.

Hosted by Rafael Rosengarten

Nature examines the booming market for unregulated peptides and asks whether scientific evidence supports the health and wellness claims driving their popularity.